Evidence map›Paper›PMID 33033913›Full record

ArticleSurgical endoscopy2021

Regression of Barrett's esophagus after magnetic sphincter augmentation: intermediate-term results.

Colin P Dunn, Justin C Henning, Jason A Sterris, Paul Won, Caitlin Houghton, Nikolai A Bildzukewicz, John C Lipham

Abstract read
PubMed Publisher
In one paragraph

Article in Surgical endoscopy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Magnetic sphincter augmentation: considerations for use in Barrett's esophagus.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Colin P DunnThe Division of Upper GI and General Surgery at the University of Southern California, Los Angeles, CA, USA.
Justin C HenningThe Division of Upper GI and General Surgery at the University of Southern California, Los Angeles, CA, USA.
Jason A SterrisThe Division of Upper GI and General Surgery at the University of Southern California, Los Angeles, CA, USA.
Paul WonThe Division of Upper GI and General Surgery at the University of Southern California, Los Angeles, CA, USA.
Caitlin HoughtonThe Division of Upper GI and General Surgery at the University of Southern California, Los Angeles, CA, USA.
Nikolai A BildzukewiczThe Division of Upper GI and General Surgery at the University of Southern California, Los Angeles, CA, USA.
John C LiphamThe Division of Upper GI and General Surgery at the University of Southern California, Los Angeles, CA, USA. John.Lipham@med.usc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUntreated gastroesophageal reflux disease (GERD) can lead to Barrett's esophagus and an increased risk for esophageal adenocarcinoma. Magnetic sphincter augmentation (MSA) is a safe and effective modality for the treatment of GERD. Preliminary research on short-term outcomes after MSA demonstrated significant regression of Barrett's. Further investigation is required to evaluate the long-term effect of this treatment.

methodsA retrospective review of patients was conducted with biopsy-proven Barrett's esophagus who underwent MSA between 2007 and 2019. As a part of their preoperative evaluation, patients underwent esophagogastroduodenoscopy (EGD) with biopsies of the distal esophagus and gastroesophageal junction including any abnormal-appearing segments, pH testing, and a videoesophagram. Patients were categorized according to the length of Barrett's identified (ultrashort < 1 cm, short 1-3 cm, long > 3 cm). Improvement was defined as a decrease in length (e.g. long to short).

resultsThere were 87 patients identified for study inclusion. 55 patients were male. The median body mass index was 26.95. The median age was 61.81 (49.79-68.29). Mean follow-up time was 2.35 ± (1.57) years. 7 (8.0%) of these patients began with long segment Barrett's, 58 (66.7%) began with short segment disease, and 22 (25.3%) began with an ultrashort segment. Within this cohort, 74 (85.06%) had undergone postoperative biopsy. 7 out of 74 patients (9.46%) showed improvement in their intestinal metaplasia and 45/74 (60.81%) showed complete regression. Fisher's exact test showed a significant decrease in Barrett's length following MSA (p = 0.002). No patients progressed to dysplasia or neoplasia. There was a statistically significant decrease in the median Demeester score from 34.00 to 13.70 after surgery (p < .001).

conclusionMSA reduces esophageal acid exposure and can lead to reduction or resolution of Barrett's esophagus. MSA is also effective at preventing progression of metaplasia to dysplasia or neoplasia. This effect remains consistent even after 2 years of follow-up.

Indexed as

Barrett EsophagusEsophageal NeoplasmsGastroesophageal RefluxHumansMagnetic PhenomenaMaleMiddle AgedRetrospective StudiesAnti-reflux surgeryBarrett’s esophagusIntestinal metaplasiaMagnetic sphincter augmentation

Identifiers

PMID33033913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.